Cite
HARVARD Citation
Rowbottom, C. et al. (2021). Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats. Pharmacology research & perspectives. 9 (2), p. n/a. [Online].